Literature DB >> 12359826

Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant.

Georgia B Vogelsang1, Linda Lee, Debra M Bensen-Kennedy.   

Abstract

Stem cell transplantation is being used to treat a number of hematologic malignancies as well as hematologic and immune deficiency states. The ages of patients being offered this therapy and the donor marrow sources have been expanded. One persistent problem has been graft-versus-host disease (GVHD). This article reviews the basic biology of GVHD, clinical manifestations of acute and chronic GVHD, prophylaxis and treatment of acute GVHD, and treatment of chronic GVHD.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 12359826     DOI： 10.1146/annurev.med.54.101601.152339

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN： 0066-4219            Impact factor:   13.739


  47 in total

1.  Impaired regulatory T cell reconstitution in patients with acute graft-versus-host disease and cytomegalovirus infection after allogeneic bone marrow transplantation.

Authors:  Alain M Ngoma; Kazuhiko Ikeda; Yuko Hashimoto; Kazuhiro Mochizuki; Hiroshi Takahashi; Hideki Sano; Hayato Matsumoto; Hideyoshi Noji; Syunnichi Saito; Atsushi Kikuta; Kazuei Ogawa; Mikio Ohtsuka; Masafumi Abe; Kenneth E Nollet; Hitoshi Ohto
Journal:  Int J Hematol       Date:  2011-12-14       Impact factor: 2.490

2.  A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.

Authors:  Mark A Schroeder; H Jean Khoury; Madan Jagasia; Haris Ali; Gary J Schiller; Karl Staser; Jaebok Choi; Leah Gehrs; Michael C Arbushites; Ying Yan; Peter Langmuir; Nithya Srinivas; Michael Pratta; Miguel-Angel Perales; Yi-Bin Chen; Gabrielle Meyers; John F DiPersio
Journal:  Blood Adv       Date:  2020-04-28

Review 3.  Hematologic aspects of myeloablative therapy and bone marrow transplantation.

Authors:  Roger S Riley; Michael Idowu; Alden Chesney; Shawn Zhao; John McCarty; Lawrence S Lamb; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

4.  Monocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation.

Authors:  Ursula Hainz; Petra Obexer; Christiana Winkler; Peter Sedlmayr; Osamu Takikawa; Hildegard Greinix; Anita Lawitschka; Ulrike Pötschger; Dietmar Fuchs; Stephan Ladisch; Andreas Heitger
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

5.  Nephrotic syndrome in a child after umbilical-cord-blood transplantation.

Authors:  Joo Hoon Lee; Bo Sang Kwon; Il Soo Ha; Hae Il Cheong; Kyung Chul Moon; Hyo Seop Ahn; Yong Choi
Journal:  Pediatr Nephrol       Date:  2006-06-22       Impact factor: 3.714

6.  Inhibition of EGFR Tyrosine Kinase by Erlotinib Prevents Sclerodermatous Graft-Versus-Host Disease in a Mouse Model.

Authors:  Florence Morin; Niloufar Kavian; Wioleta Marut; Christiane Chéreau; Olivier Cerles; Philippe Grange; Bernard Weill; Carole Nicco; Frédéric Batteux
Journal:  J Invest Dermatol       Date:  2015-05-04       Impact factor: 8.551

Review 7.  Oral Complications of Chronic Graft-Versus-Host Disease.

Authors:  Jane M Fall-Dickson; Steven Z Pavletic; Jacqueline W Mays; Mark M Schubert
Journal:  J Natl Cancer Inst Monogr       Date:  2019-08-01

8.  In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations.

Authors:  Michael J Carlson; Michelle L West; James M Coghill; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

9.  Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.

Authors:  Kirsten M Williams; Jason W Chien; Mark T Gladwin; Steven Z Pavletic
Journal:  JAMA       Date:  2009-07-15       Impact factor: 56.272

10.  Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose.

Authors:  Merav Bar; Brenda M Sandmaier; Yoshihiro Inamoto; Benedetto Bruno; Parameswaran Hari; Thomas Chauncey; Paul J Martin; Rainer Storb; David G Maloney; Barry Storer; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.